PRESS RELEASE: 1 out of 3 men with breast cancer does not receive adequate treatment
Researchers confirm the poor quality of care for men affected [...]
Spotlight on Lung Cancer: Interview with Benjamin Besse
Professor Benjamin Besse, with the support of Professor Silvia Novello, [...]
European and Japanese Clinical Research Organisations Meet to Collaborate on Future Studies in Cancer.
On 2nd December 2017, at the National Cancer Center Hospital [...]
Roger Wilson on the challenges of being a cancer survivor
Roger Wilson was diagnosed with a soft tissue sarcoma in [...]
Investing in the future leaders of oncology
One of the issues that organisations face today is how [...]
Interview with Jean-Jacques Stelmes, a fellow at EORTC HQ
My name is Jean-Jacques Stelmes. I am 34 years old [...]
Foundation Medicine and European Organisation for Research and Treatment of Cancer (EORTC) Announce Collaboration to Advance Precision Medicine Using Comprehensive Genomic Profiling to Facilitate Clinical Trial Enrollment GalleryFoundation Medicine and European Organisation for Research and Treatment of Cancer (EORTC) Announce Collaboration to Advance Precision Medicine Using Comprehensive Genomic Profiling to Facilitate Clinical Trial Enrollment
Foundation Medicine and European Organisation for Research and Treatment of Cancer (EORTC) Announce Collaboration to Advance Precision Medicine Using Comprehensive Genomic Profiling to Facilitate Clinical Trial Enrollment
CAMBRIDGE, Mass. – January 30, 2018 - Foundation Medicine, Inc. [...]
Why does cancer survivorship matter?
Roger Wilson, a Session’s Chair of the EORTC Cancer Survivorship [...]
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054) GalleryMerck’s KEYTRUDA® (pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054)
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054)
KENILWORTH, N.J., and BRUSSELS, Jan. 8, 2018 – Merck (NYSE: [...]
Largest trial ever performed in alveolar soft part sarcoma: results published
EORTC 90101 “CREATE” phase II trial on the activity and [...]
